Výsledky vyhledávání - "Archana Raamanathan"

Programmable Bio-Nano-Chip Systems for Serum CA125 Quantification: Toward Ovarian Cancer Diagnostics at the Point-of-Care

Autor: Wieslaw B. Furmaga, Karen H. Lu, Glennon W. Simmons, Nicolaos Christodoulides, Robert C. Bast, Spencer W. Redding, Archana Raamanathan, Pierre N. Floriano, John T. McDevitt

Publikováno v: Cancer Prevention Research. 5:706-716

Point-of-care (POC) implementation of early detection and screening methodologies for ovarian cancer may enable improved survival rates through early intervention. Current laboratory-confined immunoanalyzers have long turnaround times and are often i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c23d6be2e6913da12eae7f96b22ccf5
https://doi.org/10.1158/1940-6207.capr-11-0508

Zobrazit plný text záznamu

Validation of a multi-marker panel for early detection of ovarian cancer

Autor: Keith A. Baggerly, Zhen Zhang, Aleksandra Gentry-Maharaj, Steven J. Skates, Robert C. Bast, Andy Ryan, Ian Jacobs, Usha Menon, Rania Fourkala, Archana Raamanathan

Publikováno v: ResearcherID

5570Background: Ovarian cancer is a high mortality gynecological malignancy with poor survival rates, where patients might benefit from early stage detection strategies. The United Kingdom Collabor...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4058a9fb490d157f9e50386f85a55a47
https://doi.org/10.1200/jco.2016.34.15_suppl.5570

Zobrazit plný text záznamu

Nano-bio-chips for high performance multiplexed protein detection: determinations of cancer biomarkers in serum and saliva using quantum dot bioconjugate labels

Autor: Carole Gage, John T. McDevitt, Amanda A. Pollard, Glennon W. Simmons, Jorge Wong, Spencer W. Redding, Jesse V. Jokerst, Nicolaos Christodoulides, Pierre N. Floriano, Archana Raamanathan, Wieslaw B. Furmaga

Publikováno v: Biosensorsbioelectronics. 24(12)

The integration of semiconductor nanoparticle quantum dots (QDs) into a modular, microfluidic biosensor for the multiplexed quantitation of three important cancer markers, carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), and Her-2/Neu (C-e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cd7582e1ddaf92299f9aaa385266b73
https://pubmed.ncbi.nlm.nih.gov/19576756

Zobrazit plný text záznamu

Abstract 3473: Intra-person and inter-person biomarker variation for modeling longitudinal values of ovarian cancer early detection biomarkers

Autor: Zhen Lu, Robert C. Bast, Steven J. Skates, Archana Raamanathan

Publikováno v: Cancer Research. 73:3473-3473

In 2012, an estimated 22,280 women will be diagnosed with ovarian cancer in the United States and 15,500 women will die from this disease. Though localized ovarian cancers have a survival rate of 92%, only 15-20% of ovarian cancers are detected at th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6bcd79603018bad6bd6306130f1c01bd
https://doi.org/10.1158/1538-7445.am2013-3473

Zobrazit plný text záznamu

Abstract 3495: Multiplexed detection of early-stage ovarian cancer biomarkers using a microfluidic bead-based immunosensor

Autor: Robert C. Bast, John T. McDevitt, Glennon W. Simmons, Basil Shadfan, Archana Raamanathan

Publikováno v: Cancer Research. 73:3495-3495

The high mortality rate of ovarian cancer is directly related to the lack of an effective screening strategy, as up to 90% of cancers that have not metastasized beyond the ovaries can be treated effectively using current strategies. While the biomark

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f39d0a3d66304cb6fd8d5c4e77df48f9
https://doi.org/10.1158/1538-7445.am2013-3495

Zobrazit plný text záznamu

Abstract 4067: Integrated microfluidic bead-based immunosensor for multiplexed determinations of ovarian cancer biomarkers at the point-of-care

Autor: Andy Ho, Glennon W. Simmons, Robert C. Bast, Archana Raamanathan, Basil Shadfan, John T. McDevitt

Publikováno v: Cancer Research. 72:4067-4067

Early detection of ovarian cancer could significantly impact clinical outcome and hence patient survival. Given the biological heterogeneity of ovarian cancer, multi-marker panels will be required. Validation of such panels must utilize pre-clinical

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5ca75c8a91c436e2fa7fdb92ec2db9a7
https://doi.org/10.1158/1538-7445.am2012-4067

Zobrazit plný text záznamu

Clinical factors affecting HE4 and CA125 in women at high risk of developing ovarian cancer

Autor: Archana Raamanathan, Yu Shen, Robert C. Bast, Karen H. Lu, Keith A. Baggerly, Laura L. Holman, Diana L. Urbauer

Publikováno v: ResearcherID

1569 Background: CA125 is often used to screen high-risk patients (pts) for ovarian cancer (OC), but levels are affected by many factors, especially in premenopausal pts. In prior studies of low-risk pts, HE4 is more stable than CA125. The objective

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::688dc3efd45b1c2ae65657ea37dfc39b
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000335419600628&KeyUID=WOS:000335419600628

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání